Sort
8,912 grants matching “sars cov 2”
Task B08: Development and Use of a Non-Human Primate Model of SARS-CoV-2 Infection
$4,821,458Karen Thompson · Battelle Centers/Pub Hlth Res & Evaluatn · N01 · FY2020 · AI
Exploring novel nucleic acid therapeutic delivery methods and therapeutic strategies
$4,810,759Peter Sarnow · Stanford University · U19 · FY2022 · AI
Conjugate nanoparticle platform development for HIV-1 envelope immunogens
$4,794,780Kevin O Saunders · Duke University · U19 · FY2024 · AI
Scientific Cyberinfrastructure Research Program
$4,764,641Scott Auerbach · National Institute Of Environmental Health Sciences · ZIA · FY2022 · ES
REDS-IV-P - CENTER FOR TRANSFUSION LABORATORY STUDIES (CTLS) - SARS-CoV-2/COVID-19 STUDIES
$4,748,941Michael Paul Busch · Vitalant · N01 · FY2020 · HL
1/2 REPRIEVE Extension for Trial Completion
$4,747,407Steven Kyle Grinspoon · Massachusetts General Hospital · UG3 · FY2024 · HL
Unravelling immunoregulatory circuits of tissue inflammation
$4,739,118Behdad Afzali · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2025 · DK
CEIRR: SARS-CoV-2 Research Activities
$4,733,041Adolfo Garcia-Sastre · Icahn School Of Medicine At Mount Sinai · N01 · FY2023 · AI
Procurement and Characterization of Postmortem Brain Tissue
$4,711,045Stefano Marenco · National Institute Of Mental Health · ZIC · FY2023 · MH
Pandemic Influenza Translational Research and novel universal countermeasure development
$4,672,598Matthew Memoli · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
CoVPN 3004 - A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine - LC3
$4,637,125Margaret Juliana McElrath · Fred Hutchinson Cancer Center · UM1 · FY2022 · AI
RAPID ACCELERATION OF DIAGNOSTICS (RADX) CLINICAL EVALUATION SERVICES
$4,625,250Mark Marino · Venturewell · N02 · FY2021 · HL
Conjugate nanoparticle platform development for HIV-1 envelope immunogens
$4,623,440Kevin O Saunders · Duke University · U19 · FY2025 · AI
PanCorVac (Center for Pan-Coronavirus Vaccine Development)
$4,618,169Yoshihiro Kawaoka · University Of Wisconsin-Madison · P01 · FY2023 · AI
Development of In Vitro Diagnostics for the Detection of SARS-CoV-2
$4,590,862Scott Schaus · Sorrento Therapeutics, Inc. · N01 · FY2023 · AI
RFA-IP-24-046: Nationwide Cohort of Blood Donors to Estimate Burden of Respiratory Viruses and Immunologic Response
$4,500,000Michael Paul Busch · Vitalant · U01 · FY2024 · IP
IP24-045, A Prospective Observational Study of Respiratory Virus Epidemiology in the Greater Boston Area
$4,500,000Kathryn Elaine Stephenson · Beth Israel Deaconess Medical Center · U01 · FY2024 · IP
Understanding Risk Gradients from Environment on Native American Child Health Trajectories: Toxicants, Immunomodulation, Metabolic syndromes, & Metals Exposure
$4,489,419Debra Mackenzie · University Of New Mexico Health Scis Ctr · UG3 · FY2023 · OD
Core 3: Non-human Primate Core
$4,487,359Barton F Haynes · Duke University · P01 · FY2021 · AI
Procurement and Characterization of Postmortem Brain Tissue
$4,484,811Stefano Marenco · National Institute Of Mental Health · ZIC · FY2022 · MH
Southwest Health Equity Research Collaborative (SHERC)
$4,473,959Julie Ann Baldwin · Northern Arizona University · U54 · FY2022 · MD
Understanding Risk Gradients from Environment on Native American Child Health Trajectories: Toxicants, Immunomodulation, Metabolic syndromes, & Metals Exposure
$4,413,294Debra Mackenzie · University Of New Mexico Health Scis Ctr · UG3 · FY2024 · OD
Inhibitors of SARS-CoV-2 proteases
$4,401,146Arnab Kumar Chatterjee · Scripps Research Institute, The · U19 · FY2022 · AI
Human Virome Characterization Center for the Oral-Gut-Brain Axis
$4,399,997Yvonne L Kapila · University Of California Los Angeles · U54 · FY2025 · AG
Development and Production of SARS-CoV2 Biologicals and Vaccines
$4,391,926Jason Gall · National Institute Of Allergy And Infectious Diseases · ZIB · FY2022 · AI